Empath Ventures

Psylo is a drug development company that specializes in next-generation psychedelics aimed at treating mental illness. The company focuses on creating novel therapeutic solutions for psychiatric and neurological disorders, with an emphasis on non-hallucinogenic and rapid-acting agents. Psylo's mission is to develop improved medications that can serve as effective alternatives to traditional selective serotonin reuptake inhibitors (SSRIs), thereby enhancing treatment options for mood disorders, addiction, and certain neurological diseases. By leveraging psychedelic molecules as the foundation for its innovative therapies, Psylo seeks to make significant advancements in mental health treatment.

Aperture Therapeutics is a biotechnology company dedicated to developing novel therapies for age-related neurodegenerative diseases. It employs a distinctive drug discovery platform that leverages the genetic diversity of patients to identify new disease pathways and drug targets. Currently in the pre-clinical stage, the company operates from a lab incubator, integrating insights from neuroscience and immunology to advance its research. Aperture Therapeutics' approach centers on the significance of genetic diversity in the discovery process, aiming to create more effective treatments for neurodegeneration and neuroimmunology conditions.

Motif Neurotech is a company focused on developing minimally invasive bioelectronic implants aimed at monitoring and treating severe mental illnesses, particularly treatment-resistant depression. Through its innovative approach, the company specializes in wireless power and data transmission, which facilitates the creation of new, miniature implants designed for tissue stimulation and diagnostic readings. This technology enables patients to potentially repair neural circuits using minimally invasive electronic therapies, offering hope for more effective treatment options for those struggling with mental health challenges.

TARA Mind is a public benefit corporation focused on enhancing access to psychedelic-assisted therapy for individuals facing treatment-resistant depression. The company addresses critical gaps in therapeutic accessibility and affordability within the high-risk mental health segment of the workforce. Through its innovative platform, TARA Mind builds a network of vetted providers across the United States, ensuring safe and effective delivery of therapies. It equips these providers with proprietary digital measurement-based care tools, which support a data-driven framework that facilitates value-based reimbursements. This enables employers to offer these transformative therapies as a covered insurance benefit, thereby promoting mental health support in the workplace.

Nue Life is a company focused on enhancing mental wellness through scientifically validated treatments. It offers an innovative therapeutic ecosystem that includes at-home ketamine therapy, an interactive companion app, and virtual aftercare programs. The application utilizes knowledge graphs and artificial intelligence to provide personalized, evidence-based therapies, assisting users in diagnosing and addressing their mental health conditions. By combining advanced technology with therapeutic practices, Nue Life aims to improve brain function, performance, and overall longevity for its users.

Motif Neurotech is a company focused on developing minimally invasive bioelectronic implants aimed at monitoring and treating severe mental illnesses, particularly treatment-resistant depression. Through its innovative approach, the company specializes in wireless power and data transmission, which facilitates the creation of new, miniature implants designed for tissue stimulation and diagnostic readings. This technology enables patients to potentially repair neural circuits using minimally invasive electronic therapies, offering hope for more effective treatment options for those struggling with mental health challenges.

Superpower is a developer of a digital clinic focused on personalized healthcare solutions. The company's platform provides users with a comprehensive health dashboard and a tailored action plan, along with access to curated tests, products, and protocols. By offering advanced diagnostics and vetted therapeutics, Superpower aims to empower individuals to pursue longer, healthier, and more vital lives. The platform is designed to enhance the management of personal health, making it more convenient and effective for users seeking to improve their overall well-being.

Psylo is a drug development company that specializes in next-generation psychedelics aimed at treating mental illness. The company focuses on creating novel therapeutic solutions for psychiatric and neurological disorders, with an emphasis on non-hallucinogenic and rapid-acting agents. Psylo's mission is to develop improved medications that can serve as effective alternatives to traditional selective serotonin reuptake inhibitors (SSRIs), thereby enhancing treatment options for mood disorders, addiction, and certain neurological diseases. By leveraging psychedelic molecules as the foundation for its innovative therapies, Psylo seeks to make significant advancements in mental health treatment.

Pangea Botanica helps to accelerate the discovery and development of therapeutics for patients by using naturally occurring compounds and traditional remedies, while preserving ethnobotanical knowledge and ecosystems. It is a biotechnology research organisation that offers drug discovery and development services.

Freedom Biosciences is a biotechnology company focused on developing next-generation psychedelic therapeutics. The company aims to create advanced psychedelic pharmaceuticals by harnessing the established pharmacology of compounds such as ketamine. Its mission is to provide innovative treatment options for medical professionals working with patients suffering from resistant depression and various mental disorders. Through its platform, Freedom Biosciences seeks to contribute to the evolving landscape of mental health treatment, addressing the needs of individuals who do not respond to conventional therapies.

Kanna Health is a preclinical stage biotechnology company focused on developing innovative therapeutics derived from kanna, or Sceletium tortuosum, a medicinal succulent historically utilized by the San hunter-gatherers of South Africa. The company aims to address significant unmet needs in sexual and mental health through its lead candidate, KH-001, which is formulated from alkaloids found in kanna. This candidate is designed to enhance mood and performance in males, offering potential for affordable treatment options. Kanna Health's mission centers on leveraging the traditional use of kanna to create modern therapeutic solutions that improve health outcomes.

Wavepaths, established in 2018 and based in London, specializes in developing accessible technology for psychedelic therapy. The company creates personalized soundtracks using intelligent technologies and immersive media, aiming to facilitate inner exploration and emotional reconnection during drug-free therapeutic sessions. Their offerings span the fields of information technology, healthcare, and personal health.

Beond is a provider of wellness and healing treatments that focus on using ibogaine to address anxiety and other behavioral conditions. The company aims to facilitate profound transformational change for individuals grappling with issues such as chemical dependency, substance abuse, depression, anxiety, and PTSD. By offering counseling, education, and support, Beond seeks to help clients recover from addiction and heal from trauma, enabling them to overcome their mental health challenges and improve their overall well-being.

MycroDose Therapeutics is a U.S.-based pharmaceutical company focused on developing advanced drug delivery systems that utilize psychedelic compounds for the treatment of mental health disorders and cognitive degenerative diseases. The company is actively working on two of its four core technologies, which include a psilocybin transdermal delivery system and a ketamine oral mucosa delivery system. By leveraging these innovative approaches, MycroDose Therapeutics aims to enhance the efficacy and accessibility of treatments for patients dealing with these challenging conditions.

Quantified Citizen is a developer of a mobile health research platform that aims to enhance scientific research by making it more accessible and participatory. The company empowers both citizen scientists and professional researchers to easily create and engage in their own scientific studies, thereby fostering a community dedicated to timely insights in health research. Its platform utilizes standardized health measures, allowing users to rapidly deploy behavioral research studies. Additionally, it provides a growing library of studies focused on various interventions, such as psychedelics and micro-dosing for mental health, enabling individuals to select studies that align with their interests while contributing to the advancement of global health and science.